Scinai Immunotherapeutics (SCNI) Common Equity (2016 - 2025)

Scinai Immunotherapeutics has disclosed Common Equity across 9 years of filings, most recently posting $22.1 million for Q4 2025.

• Common Equity for Q4 2025 came in at $22.1 million, up 121.4% year-over-year; the trailing twelve-month figure through Dec 2025 was $22.1 million (up 121.4% YoY), and the FY2025 annual result was $22.1 million, up 121.4% from the prior year.
• Common Equity came in at $22.1 million for Q4 2025 at Scinai Immunotherapeutics, up from $7.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $747.2 million in Q2 2022 to a low of -$7.3 million in Q2 2024.
• The 5-year median for Common Equity is -$862000.0 (2022), against an average of $51.1 million.
• Across the five-year window, Common Equity slumped 458.0% in 2023 and jumped 471.58% in 2024, its largest moves.
• Scinai Immunotherapeutics' Common Equity stood at $982000.0 in 2021, then sank by 279.23% to -$1.8 million in 2022, then slumped by 159.6% to -$4.6 million in 2023, then soared by 318.36% to $10.0 million in 2024, then jumped by 121.4% to $22.1 million in 2025.
• The last three Common Equity figures came in at $22.1 million (Q4 2025), $7.9 million (Q2 2025), and $10.0 million (Q4 2024), per Business Quant data.